L. Puig Dose escalation may be effective in patients with psoriasis after treatment failure or suboptimal response, but switching to adalimumab is the most cost-effective measure in different scenarios British Journal of Dermatology 168
Article first published online: 28 FEB 2013 | DOI: 10.1111/bjd.12023
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.